MESO

Mesoblast Limited

7.55 USD
+0.09 (+1.21%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Mesoblast Limited stock is up 5.15% since 30 days ago. The next earnings date is Jul 23, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 8 July’s closed higher than June. 100% of analysts rate it a buy.

About Mesoblast Limited

Mesoblast Limited offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection. The company has strategic partnerships with Tasly Pharmaceutical Group, JCR Pharmaceuticals Co. Ltd. and Grünenthal.